Market Overview:
The global diabetic neuropathy market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetic neuropathy treatment. Based on type, the global diabetic neuropathy market is segmented into peripheral neuropathy, autonomic neuropathy, proximal neuropathy, and focal neuropathy. Peripheral Neuropathies are further sub-segmented into sensory nerve damage (painful feet), motor nerve damage (weakness or paralysis), and autonomic nerve damage (digestive problems). Autonomic Neuropathies are further sub-segmented into cardiovascular autonomic dysfunction (CAD), gastroparesis/intestinal dysmotility syndrome (G/IDS), bladder dysfunction syndromes including overactive bladder syndrome and detrusor sphincter dyssynergia (DSD)], sexual dysfunction syndromes including erectile dysfunction and loss of libido], hypoglycemia unawareness or hypoglycemic unawareness]. Proximal Neuropathies are further sub-segmented into Charcot Marie Tooth disease type 1A & B1(CMT1A&B1)and Hereditary Motor Sensory Neuropathies(HMSNs)).
Product Definition:
Diabetic neuropathy is a type of nerve damage that can occur in people who have diabetes. It's caused by high blood sugar levels over time.
Peripheral Neuropathy:
Peripheral neuropathy is a type of diabetic neuropathy that affects the peripheral nervous system. It is one of the most common complications associated with diabetes mellitus and its prevalence increases with age. According to statistics by WHO, it has been estimated that globally around 463 million people are living with diabetes and this number will rise to 700 million within 20 years.
Autonomic Neuropathy:
Autonomic neuropathy is a type of diabetic neuropathy that affects the autonomic nervous system, which includes the nerves that control the automatic functions of the body such as digestion, heart rate, blood pressure and temperature. It can also affect bladder & bowel movements and sexual function.
According to studies conducted by American Diabetes Association in 2013 around 1 million people were suffering from diabetic neuropathy in U.
Application Insights:
Based on application, the global diabetic neuropathy market is segmented into hospitals, clinics, retail pharmacies and online pharmacies. Hospitals held the largest share in 2017 owing to factors such as a large patient base and availability of advanced healthcare facilities. In addition, hospital-based settings offer better monitoring options for patients suffering from diabetes-related complications due to less mobility involved in these settings.
The clinics segment is expected to grow at a lucrative rate over the forecast period owing to rising awareness about early diagnosis of diabetic retinopathy and macular degeneration among patients along with increasing adoption of preventive care measures by doctors associated with this industry.
Regional Analysis:
North America dominated the global diabetic neuropathy market in 2017. The presence of a large number of key players, availability of advanced treatment options, rising prevalence of diabetes and its associated risks such as cardiovascular diseases and kidney problems are some factors attributing to the dominance. In addition, increasing awareness about various treatment options is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to an increase in healthcare expenditure by governments along with other initiatives taken by non-profit organizations for raising awareness about early diagnosis related interventions for diabetic peripheral neuropathy among patients suffering from type 2 diabetes are expected contribute towards regional market growth during the forecast period.
The Asia Pacific was estimated at USD X billion in 2014.
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is primarily because of the changing lifestyle and dietary habits. As a result, the number of people suffering from diabetic neuropathy is also on the rise.
- Growing awareness about diabetic neuropathy: There is growing awareness among people about diabetic neuropathy and its symptoms. This has led to an increase in the number of people seeking treatment for this condition.
- Improved diagnosis and treatment options: The diagnosis and treatment options for diabetic neuropathy have improved significantly in recent years. This has helped to improve the prognosis for patients with this condition.
Scope Of The Report
Report Attributes
Report Details
Report Title
Diabetic Neuropathy Market Research Report
By Type
Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
By Application
Hospitals, Clinics, Retail Pharmacy, Online Pharmacy
By Companies
Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS, Cephalon, MEDA Pharma & Co. KG, GlaxoSmithKline, NeuroMetrix, Johnson and Johnson
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
230
Number of Tables & Figures
161
Customization Available
Yes, the report can be customized as per your need.
Global Diabetic Neuropathy Market Report Segments:
The global Diabetic Neuropathy market is segmented on the basis of:
Types
Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Retail Pharmacy, Online Pharmacy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Janssen Pharmaceuticals
- Eli Lilly and Company
- ACTAVIS
- Cephalon
- MEDA Pharma & Co. KG
- GlaxoSmithKline
- NeuroMetrix
- Johnson and Johnson
Highlights of The Diabetic Neuropathy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Peripheral Neuropathy
- Autonomic Neuropathy
- Proximal Neuropathy
- Focal Neuropathy
- By Application:
- Hospitals
- Clinics
- Retail Pharmacy
- Online Pharmacy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Diabetic Neuropathy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Diabetic neuropathy is a condition that affects the nerves in the feet and lower legs. It can cause pain, numbness, and tingling. Diabetic neuropathy may also lead to decreased sensation in your feet and toes.
Some of the key players operating in the diabetic neuropathy market are Pfizer, Janssen Pharmaceuticals, Eli Lilly and Company, ACTAVIS, Cephalon, MEDA Pharma & Co. KG, GlaxoSmithKline, NeuroMetrix, Johnson and Johnson.
The diabetic neuropathy market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Diabetic Neuropathy Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Diabetic Neuropathy Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Diabetic Neuropathy Market - Supply Chain
4.5. Global Diabetic Neuropathy Market Forecast
4.5.1. Diabetic Neuropathy Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Diabetic Neuropathy Market Size (000 Units) and Y-o-Y Growth
4.5.3. Diabetic Neuropathy Market Absolute $ Opportunity
5. Global Diabetic Neuropathy Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Diabetic Neuropathy Market Size and Volume Forecast by Type
5.3.1. Peripheral Neuropathy
5.3.2. Autonomic Neuropathy
5.3.3. Proximal Neuropathy
5.3.4. Focal Neuropathy
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Diabetic Neuropathy Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Diabetic Neuropathy Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Clinics
6.3.3. Retail Pharmacy
6.3.4. Online Pharmacy
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Diabetic Neuropathy Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Diabetic Neuropathy Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Diabetic Neuropathy Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Diabetic Neuropathy Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Diabetic Neuropathy Demand Share Forecast, 2019-2026
9. North America Diabetic Neuropathy Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Diabetic Neuropathy Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Diabetic Neuropathy Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Retail Pharmacy
9.4.4. Online Pharmacy
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Diabetic Neuropathy Market Size and Volume Forecast by Type
9.7.1. Peripheral Neuropathy
9.7.2. Autonomic Neuropathy
9.7.3. Proximal Neuropathy
9.7.4. Focal Neuropathy
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Diabetic Neuropathy Demand Share Forecast, 2019-2026
10. Latin America Diabetic Neuropathy Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Diabetic Neuropathy Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Diabetic Neuropathy Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Retail Pharmacy
10.4.4. Online Pharmacy
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Diabetic Neuropathy Market Size and Volume Forecast by Type
10.7.1. Peripheral Neuropathy
10.7.2. Autonomic Neuropathy
10.7.3. Proximal Neuropathy
10.7.4. Focal Neuropathy
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Diabetic Neuropathy Demand Share Forecast, 2019-2026
11. Europe Diabetic Neuropathy Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Diabetic Neuropathy Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Diabetic Neuropathy Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Retail Pharmacy
11.4.4. Online Pharmacy
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Diabetic Neuropathy Market Size and Volume Forecast by Type
11.7.1. Peripheral Neuropathy
11.7.2. Autonomic Neuropathy
11.7.3. Proximal Neuropathy
11.7.4. Focal Neuropathy
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Diabetic Neuropathy Demand Share, 2019-2026
12. Asia Pacific Diabetic Neuropathy Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Diabetic Neuropathy Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Diabetic Neuropathy Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Retail Pharmacy
12.4.4. Online Pharmacy
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Diabetic Neuropathy Market Size and Volume Forecast by Type
12.7.1. Peripheral Neuropathy
12.7.2. Autonomic Neuropathy
12.7.3. Proximal Neuropathy
12.7.4. Focal Neuropathy
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Diabetic Neuropathy Demand Share, 2019-2026
13. Middle East & Africa Diabetic Neuropathy Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Diabetic Neuropathy Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Diabetic Neuropathy Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Retail Pharmacy
13.4.4. Online Pharmacy
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Diabetic Neuropathy Market Size and Volume Forecast by Type
13.7.1. Peripheral Neuropathy
13.7.2. Autonomic Neuropathy
13.7.3. Proximal Neuropathy
13.7.4. Focal Neuropathy
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Diabetic Neuropathy Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Diabetic Neuropathy Market: Market Share Analysis
14.2. Diabetic Neuropathy Distributors and Customers
14.3. Diabetic Neuropathy Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Janssen Pharmaceuticals
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Eli Lilly and Company
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. ACTAVIS
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Cephalon
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. MEDA Pharma & Co. KG
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. GlaxoSmithKline
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. NeuroMetrix
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Johnson and Johnson
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
